Therapeutic nanomedicine for brain cancer

Stephany Y. Tzeng, Jordan J. Green

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations


Malignant brain cancer treatment is limited by a number of barriers, including the blood-brain barrier, transport within the brain interstitium, difficulties in delivering therapeutics specifically to tumor cells, the highly invasive quality of gliomas and drug resistance. As a result, the prognosis for patients with high-grade gliomas is poor and has improved little in recent years. Nanomedicine approaches have been developed in the laboratory, with some technologies being translated to the clinic, in order to address these needs. This review discusses the obstacles to effective treatment that are currently faced in the field, as well as various nanomedicine techniques that have been used or are being explored to overcome them, with a focus on liposomal and polymeric nanoparticles.

Original languageEnglish (US)
Pages (from-to)687-704
Number of pages18
JournalTherapeutic Delivery
Issue number6
StatePublished - Jun 2013
Externally publishedYes

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Therapeutic nanomedicine for brain cancer'. Together they form a unique fingerprint.

Cite this